Observations of nonadherence to recombinant human growth hormone therapy in clinical practice.

Background: The effectiveness of all prescribed treatments is contingent on patient adherence. The reported levels of adherence to recombinant human growth hormone (r-hGH) therapy are highly variable, but it has been suggested that nonadherence might be as high as 36% to 49%.

Objectives: This commentary discusses the factors that affect long-term adherence to injection treatment, of which r-hGH therapy is a particular challenge.

Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial.

Background: Achondroplasia is a skeletal dysplasia with extreme, disproportionate, short stature.

Aim: In a 5-y growth hormone (GH) treatment study including 1 y without treatment, we investigated growth and body proportion response in 35 children with achondroplasia.

Methods: Patients were randomized to either 0.

Chronic mucocutaneous candidiasis and primary hypothyroidism in two families.

Unlabelled: We describe the clinical and immunological features of two families with chronic mucocutaneous candidiasis (CMC) and primary hypothyroidism. Family A includes three siblings with both candidiasis and hypothyroidism and four individuals with hypothyroidism only. Family B includes four members with candidiasis, of whom one (a male child) also had hypothyroidism.